The supplied source describes semaglutide as a peptide designed to reproduce endogenous GLP-1 signaling and names Ozempic, Wegovy, and Rybelsus as aliases. It records FDA-approved status for type 2 diabetes and chronic weight management, with cardiovascular benefit also listed on the label.

What biological actions are reported for semaglutide?

According to the supplied description, GLP-1 receptor activation is associated with greater insulin release when glucose is high, lower glucagon output, delayed stomach emptying, and appetite-related hypothalamic signaling. The source attributes the prolonged action to a fatty-acid chain that binds albumin, reporting an approximately 160 hour (about 160 hours) half-life.

What safety effects does the supplied source list for semaglutide?

The reported list includes nausea, vomiting, diarrhea, constipation, abdominal pain, headache, fatigue, injection-site reactions, hypoglycemia with insulin/sulfonylureas, gallbladder problems, pancreatitis, acute kidney injury, and a thyroid C-cell-tumor boxed warning. The source notes that reported experiences can differ by dose, duration, and individual health factors.

What dose information is listed in the supplied source?

The community row reports 1-2.4 mg weekly (after titration), a 0.25-2.4 mg weekly range, and Once weekly frequency. The research row records Subcutaneous injection weekly, or oral (Rybelsus), alongside 0.25mg weekly (starting) and Long-term / chronic use.

Weight Loss FDA Approved - approved for specific uses

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

A long-acting GLP-1 receptor agonist peptide.

Status

FDA Approved

Evidence level: human clinical evidence

Typical dose

1–2.4mg

Subcutaneous injection weekly

Researched for

Weight loss, appetite control, blood sugar management

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

FDA approved - FDA-approved for specific uses with established human evidence

Use the tools

In plain language

Single receptor , described as mimicking endogenous GLP-1 and listed with Ozempic, Wegovy, and Rybelsus as aliases.
The supplied record labels it FDA Approved and lists research in weight loss, appetite control, and blood sugar management.
Its evidence narrative cites randomized research findings, a once-weekly schedule, and an oral Rybelsus form.
Regulatory, efficacy, and safety statements in this draft remain source-reported pending independent review.

How it's thought to work

According to the supplied description, semaglutide stimulates the receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) , supporting weekly administration.

What the research shows

Where the research stands

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

What it shows

✓ Human clinical evidence

FDA-approved for specific uses with established human evidence

△ Limitations

Use only according to approved labeling and qualified medical guidance.

Bottom line: FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. FDA Approved

Typical dosing

CommunityCommunity dataset

1–2.4 mg

weekly (after titration)

0.25 mgfull range seen2.4 mg

Community material describes a 16-20 week titration span: 0.25 mg at the outset, changes every 4 week interval, and some remaining at 1 mg when tolerated. This is a reported schedule, not individualized guidance.

Research dosing

Indication-specificApproved for specific uses - study doses are indication-specific

Doses observed in studies

0.25mg weekly (starting)

FDA Label - Ozempic/Wegovy - Initial dose for all patients

Use only according to approved labeling and qualified medical guidance.

Duration: Long-term / chronic use
Administration: Subcutaneous injection weekly, or oral (Rybelsus)

Timing & administration

Best time to take

Morning, same day each week

Once weekly, same day and time

Food recommendation

With or without food

Why this timing?

The supplied source presents consistent weekly timing and a morning schedule as a practical way to observe reported effects while awake; it does not establish a time-of-day outcome advantage.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Nausea
Vomiting
Diarrhea
Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

The supplied entry labels semaglutide FDA Approved and reports type 2 diabetes, weight loss, cardiovascular-risk, and CKD/kidney-protection labeling in Jan 2025. It also reports oral Wegovy in Dec 2025; a Wegovy HD 7.2 mg injection in Mar 2026, with STEP UP reporting 18.7 % mean weight loss and a 22.9 % dysesthesia signal; and Wegovy 2.4 mg for non-cirrhotic MASH in Apr 2026, described as the first GLP-1 for that indication. It further records tentative FDA approval of generic semaglutide for Apotex on Apr 10, 2026. These regulatory assertions are not independently corroborated in this input.

Sequence

H-Aib-EGTFTSDVSSYLEGQAAK(1)EFIAWLVRGRG; C18-diacid-gamma-Glu-2xOEG linked at Lys20

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Semaglutide

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Semaglutide

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions

What is semaglutide?